Newly diagnosed patients with PsA (n=29) | Patients who had no PsA (n=71) | p Value | |
---|---|---|---|
Age (years±SD) | 52.03±10.62 | 52.41±14.34 | 0.89 |
Male (%) | 18 (62%) | 46 (65%) | 0.79 |
On systemic therapy | |||
TNF inhibitors | 10 (34%) | 29 (41%) | 0.74 |
Fumaderm | 11 (38%) | 24 (34%) | |
Phototherapy | 3 (10%) | 9 (13%) | |
Ustekinumab | 1 (3%) | 2 (3%) | |
Ciclosporin | 0 | 2 (3%) | |
Duration of psoriasis (years±SD) | 29.10±15.08 | 28.82±14.29 | 0.92 |
PASI (score±SD) | 2.40±1.13 | 1.89±1.14 | 0.04 |
Nail disease, current (%) | 20 (69%) | 48 (67.6%) | 0.35 |
Nail disease, ever (%) | 23 (79%) | 49 (69%) | 0.06 |
Scalp Ps, current (%) | 15 (52%) | 41 (58%) | 0.58 |
Scalp Ps, ever (%) | 27 (93%) | 64 (90%) | 0.16 |
PASI, Psoriasis Area and Severity Index; TNF, tumour necrosis factor; Ps, psoriasis.